Buscar
Alkermes Plc
ALKSAñadir a la lista de seguimiento
42.565USD
-0.725-1.68%
Horarios del mercado 09/23, 10:25（ET）
7.14BCap. mercado
45.78P/E TTM
Acerca de Alkermes Plc Compañía
Alkermes plc is Ireland-based biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
Perfil de Alkermes Plc
Símbolo de cotizaciónALKS
Nombre de la empresaAlkermes Plc
Fecha de salida a bolsaJul 16, 1991
Director ejecutivoPops (Richard F)
Número de empleados1800
Tipo de seguridadOrdinary Share
Fin del año fiscalJul 16
DirecciónConnaught House
CiudadDUBLIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIreland
Código postalD04 C5Y6
Teléfono35317728000
Sitio Webhttps://www.alkermes.com/
Símbolo de cotizaciónALKS
Fecha de salida a bolsaJul 16, 1991
Director ejecutivoPops (Richard F)
Ejecutivos de Alkermes Plc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard F. Pops
Mr. Richard F. Pops
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.38M
--
Mr. Richard F. Pops
Mr. Richard F. Pops
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.38M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
223.42K
-0.91%
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
223.42K
-0.91%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
106.68K
+2.75%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
106.68K
+2.75%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
65.39K
-6.12%
Dr. Craig C. Hopkinson, M.D.
Dr. Craig C. Hopkinson, M.D.
Executive Vice President, Research and Development and Chief Medical Officer
Executive Vice President, Research and Development and Chief Medical Officer
65.39K
-6.12%
Mr. Brian P. McKeon
Mr. Brian P. McKeon
Independent Director
Independent Director
48.54K
+9.62%
Mr. Brian P. McKeon
Mr. Brian P. McKeon
Independent Director
Independent Director
48.54K
+9.62%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard F. Pops
Mr. Richard F. Pops
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.38M
--
Mr. Richard F. Pops
Mr. Richard F. Pops
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
1.38M
--
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
223.42K
-0.91%
Mr. David Joseph Gaffin
Mr. David Joseph Gaffin
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
Executive Vice President, Chief Compliance Officer, Chief Legal Officer, Secretary
223.42K
-0.91%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
106.68K
+2.75%
Mr. Shane M. Cooke
Mr. Shane M. Cooke
Independent Director
Independent Director
106.68K
+2.75%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Alkermes Plc?
Los cinco principales accionistas de Alkermes Plc son: Mr. Richard F. Pops
¿Cuántas instituciones poseen acciones de Alkermes Plc (ALKS)?
A fecha de 2026Q1, 783 instituciones poseen acciones de Alkermes Plc, con un valor de mercado combinado de aproximadamente 182.39M, lo que representa el 109.43% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -11997400.00.
¿Cuál es la mayor fuente de ganancias de Alkermes Plc?
El 2026Q1, el segmento empresarial VIVITROL generó la ganancia más alta para Alkermes Plc, ascendiendo a 124.45M y representando el 25.09% de la ganancia total.